Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,049.33 -9.23 (-0.87%)
Streaming Delayed Price Updated: 12:55 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation
As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4... 
Via Finterra
Topics Earnings Economy Initial Public Offering
News headline image
Is Johnson & Johnson Stock Outperforming the Nasdaq?
Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks World Trade
News headline image
Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗
According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Elanco (NYSE:ELAN) Surprises With Q4 CY2025 Sales
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was... 
Via StockStory
News headline image
NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗
Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China. 
Via Stocktwits
News headline image
Is Eli Lilly Stock Underperforming the S&P 500?
Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory. 
Via Barchart.com
Topics Stocks
News headline image
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗
Is this the best way to cash in on the weight-loss gold rush? 
Via The Motley Fool
News headline image
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗
Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy. 
Via The Motley Fool
Topics Stocks
News headline image
Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower ↗
AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026. 
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
News headline image
1 Reason I'd Buy Veeva Systems Stock and Never Sell ↗
It's worth sticking with the stock through the hard times. 
Via The Motley Fool
News headline image
Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?
Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels. 
Via Barchart.com
News headline image
Eli Lilly (LLY) Stock Is Up, What You Need To Know
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it... 
Via StockStory
Topics Artificial Intelligence
News headline image
The Great Reshoring: US Manufacturing Renaissance Hits High Gear Amid Tariff Volatility
WASHINGTON D.C. — In a dramatic shift of the global economic landscape, the United States is currently witnessing a massive "repatriation" of industrial capacity, commonly referred to as the US... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a... 
Via MarketMinute
News headline image
Why Viking Therapeutics Stock Is Up More Than 9% Today ↗
A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow. 
Via The Motley Fool
Which S&P500 stocks are moving on Monday? ↗
Via Chartmill
News headline image
Hedge Funds' Mag 7, Eli Lilly Buying Spree Sparks Massive ETF Accumulation In IVV, SPY, QQQ ↗
Hedge funds bet heavily on big tech, Eli Lilly, and others in Q4, driving flows into SPY, QQQ, as mega-cap stocks dominated portfolio allocations. 
Via Benzinga
Topics ETFs
News headline image
Novo Nordisk's Loss Is Eli Lilly's Gain ↗
Eli Lilly shares climb after Novo Nordisk trial miss. CagriSema trails tirzepatide in 84-week weight-loss study results. 
Via Benzinga
News headline image
Is Microsoft Down? Downdetector Reports Issues With Azure, Outlook, MSFT 365 ↗
Microsoft flagged that services that require Multi-Factor Authentication may return gateway timeout errors for users in the U.S. 
Via Stocktwits
News headline image
Why Eli Lilly Stock Just Popped ↗
Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly). 
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Just Crashed ↗
GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for. 
Via The Motley Fool
News headline image
Eli Lilly: The Weight‑Loss and Diabetes Powerhouse I'd Hold Through Any Market Crash ↗
The stock looks unstoppable. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026
As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the... 
Via Finterra
Topics Artificial Intelligence Intellectual Property Lawsuit
News headline image
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing... 
Via MarketMinute
News headline image
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated... 
Via MarketMinute
Topics Earnings
News headline image
Eli Lilly Unusual Options Activity For February 23 ↗
 
Via Benzinga
News headline image
Eli Lilly Announces New Version Of Zepbound With A Month’s Worth Of Doses In KwikPen — How Much Will It Cost? ↗
The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website. 
Via Stocktwits
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound ↗
Novo's next-gen drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. 
Via Investor's Business Daily
News headline image
1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗
Novo Nordisk investors get a second bite at the Ozempic apple. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.